Sermorelin + Ipamorelin

Sermorelin — the native fragment

Ipamorelin — the second pathway

Ipamorelin binds the growth hormone secretagogue receptor, the receptor for ghrelin. Its selectivity profile is the reason it is preferred over GHRP-6 and GHRP-2 in modern designs: comparable secretagogue potency with far less disturbance of ACTH, cortisol and prolactin, so hormone endpoints are less confounded.

Why they are paired

• Two distinct receptors on the same somatotroph, so the effects are complementary rather than redundant.
• GHS-receptor agonism lowers somatostatin tone, raising the ceiling on the GHRH response.
• Both are short-acting, preserving pulsatility — important in a feedback-regulated axis.

How this differs from the CJC-1295 blend

Warm the sealed vial to room temperature before opening so moisture does not settle on the cake. Direct bacteriostatic water down the inner glass wall rather than onto the powder and swirl gently until the solution clears — shaking shears peptide chains and causes foaming that interferes with accurate withdrawal. Sermorelin is the less stable of the two components in solution, so most protocols keep the reconstituted vial refrigerated at 2–8 °C, shielded from light, and use it within a defined study window. Log the concentration of each component separately, keep unopened vials at −20 °C, and label every working stock for laboratory research use only.